Research Program: Women's Cancer
Associate Professor, Department of Medicine
Member, Microbiology, Immunogoly and Cancer Biology Graduate Program

dapotter@umn.edu
612-625-8933 — office
612-62506919— fax
Preferred method of contact: e-mail

Dr. Potter's clinical profile
(University of Minnesota Physicians Web site)

After undergraduate studies in biology at M.I.T., Dr. Potter received M.D. and Ph.D. degrees from Johns Hopkins University. He trained in internal medicine at Stanford University Medical Center, and in hematology and oncology at Tufts-New England Medical Center. He performed postdoctoral studies at the M.I.T. Center for Cancer Research. He was on the faculty at Tufts University, the Indiana University Cancer Center, and moved to the University of Minnesota in 2006, where he is a member of the Women's Cancer Research Program at the Masonic Cancer Center.

Research Interests

Dr. Potter's research interests include: the mechanisms of cytochrome P450 epoxygenases in breast cancer progression, pre-clinical cancer drug development and translational breast cancer clinical trials. Also of interest are the mechanisms of calpain proteases in cell motility and cytoskeletal remodeling.

Selected Publications

Cech TR, Potter D, Pardue ML. Chromatin structure in living cells. Cold Spring Harb Symp Quant Biol, 1978; 42:191-197.

Berninger M, Cech TR, Fostel J, Potter D, Scott M, Pardue ML. The structure and function of the mitochondrial DNA of Drosophila melanogaster. Alfred Benzon Symposium 1978; 13:229-241.

Potter DA, Fostel J, Berninger M, Cech TR, Pardue ML. DNA-protein interactions in the Drosophila mitochondrial genome as deduced from trimethylpsoralen crosslinking patterns. Proc Natl Acad Sci USA 1980;77:4118-4122.

Morrow JF, Stearman RS, Peltzman C, Potter DA. Induction of hepatic synthesis of serum amyloid A protein and actin. Proc Natl Acad Sci USA 1981;78:4718-4722.

Lowell CA, Potter DA, Stearman RS, Morrow JF. Structure of the murine serum amyloid A gene family. Gene conversion. J Biol Chem 1986;261:8442-8452.

Potter DA, C. J. Larson CJ, Eckes P, Schmid RM, Nabel GJ, Verdine GL, Sharp PA. Purification of the MHC class I transcription factor H2TF1: the full length product of the nfkb2 gene. J Biol Chem. 1993;268:18882-18890.

Limentani S, Pretell JO, Potter D, DuBois JS, Dauost PR, Spieler PS, Miller KB. Bone marrow necrosis in two patients with acute promyelocytic leukemia during treatment with all-trans retinoic acid. Am J Hematol. 1994;47:50-55.

Potter D A, Tirnauer JS, Janssen R, Croall DE, Hughes CD, Fiacco KA, Mier JW, Maki M, Herman IM. Calpain regulates the actsin cytoskeleton during cell spreading. J Cell Biol. 1998;141:647-662.

Croce K, Flaumenhaft R, Rivers M, Furie BC, Furie B, Herman IM, Potter DA. Calpain regulates platelet secretion, aggregation and spreading. J Biol Chem. 1999;274:36321-36327.

Carragher NO, Westhoff MA, Riley D, Potter DA, Dutt P, Elce JS, Greer PA, Frame MC. v-src Induced Modulation of the Calpain-Calpastatin Proteolytic System Regulates Both Morphological Transformation and Cell Cycle Progression. Mol Cell Biol. 2002;22:257-269.

Potter DA, Srirangam A, Fiacco KA,Brocks D, Maki M, Acheson D, Herman IM.   Calpain Regulates Enterocyte Brush Border Actin Assembly and Pathogenic E. coli-Mediated Effacement. J Biol Chem. 2003;278:30403-30412.

Glading A, Bodnar R, Reynolds IJ, Shiraha H, Satish L, Potter DA, Blair HC, Wells A. EGF activates m-calpain (calpain 2), at least in part, by ERK-mediated phosphorylation. Mol Cell Biol. 2004;24:2499-2512.

Narayanasamy D, Mukhopadhyay S, Palakal M, Potter DA. TransMiner: Mining Transitive Associations among Biological Objects from Text. J Biomed Science 2004;11:864-873.

Henley JD, Summerlin DJ, Potter DA, Timmerman RD, Tomich CE. 2005. Intraoral Mucin-Rich Salivary Duct Carcinoma. Histopathology 2005;44:436-437.

Zhang B, Srirangam A, Potter DA, Roman A. HPV16 E5 Protein Disrupts the c-Cbl-EGFR Interaction and EGFR Ubiquitination in Human Foreskin Keratinocytes. Oncogene 2005;24:2585-2588.

Srirangam A, Mitra R, Wang M, Gorski JC, Badve S, Baldridge LA, Hamilton J, Kishimoto H,Hawes J, Li L, Blum JS, Donner DB, Sledge GW, Nakshatri H, Potter DA.Effects of HIV Protease Inhibitor Ritonavir on Akt-Regulated Cell Proliferation in Breast Cancer. Clin Cancer Res. 2006;12:1883-1896.

Carpenter JS, Rawl SR, Porter J, Schmidt K, Tornatta J, Ojewole F, Helft P, Potter DA, Sweeney C, Giesler RB. Oncology outpatient and provider responses to a computerized symptom assessment system. Oncol Nurs Forum. 2008;35:661-669.

Mitra R, Lee J, Jo J, Milani M, McClintick JN, Edenberg HJ, Kesler KA, Rieger KM, Badve S, Cummings OW, Mohiuddin A, Thomas DG, Luo X, Juliar BE, Li L, Mesaros C, Blair IA, Srirangam A, Kratzke R, McDonald CJ, Kim J, Potter DA. Prediction of postoperative recurrence-free survival in non-small cell lung cancer by using an internationally validated gene expression model. Clin Cancer Res. 2011;17:2934-2946.

Srirangam A, Milani M, Mitra R, Guo Z, Rodriguez M, Kathuria H, Fukuda S, Rizzardi A, Schmechel S, Skalnik DG, Pelus LM, Potter DA. The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer dells, in part, by inhibition of survivin. J Thorac Oncol. 2011;6:661-670.

Mitra R, Guo Z, Milani M, Mesaros C, Rodriguez M, Nguyen J, Luo X, Clarke D, Lamba J, Schuetz E, Donner DB, Puli N, Falck JR, Capdevila J, Gupta K, Blair IA, Potter DA. CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (+/-)-14,15-epoxyeicosatrienoic acid (EET). J Biol Chem. 2011;286:17543-17559.